Nothing Special   »   [go: up one dir, main page]

MX2014006396A - Vacunas contra el virus de la influenza y sus usos. - Google Patents

Vacunas contra el virus de la influenza y sus usos.

Info

Publication number
MX2014006396A
MX2014006396A MX2014006396A MX2014006396A MX2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A
Authority
MX
Mexico
Prior art keywords
domain
polypeptides
influenza hemagglutinin
influenza virus
virus vaccines
Prior art date
Application number
MX2014006396A
Other languages
English (en)
Other versions
MX357009B (es
Inventor
Wilem Meijberg Jan
Impagliazzo Antonietta
Vogels Ronald
Heinz Edward Friesen Robert
Alard Philippe
Loverix Stefan
Radosevic Katarina
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MX2014006396A publication Critical patent/MX2014006396A/es
Publication of MX357009B publication Critical patent/MX357009B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polipéptidos que comprenden polipéptidos del dominio de tallo de la hemaglutinina de la influenza, donde dichos polipéptidos comprenden (a) un dominio HA1 de la hemaglutinina de la influenza, que comprende un segmento del tallo N-terminal del HA1, unido covalentemente mediante una secuencia conectora de 0-50 aminoácidos a un segmento del tallo C-terminal del HA1, y (b) un dominio HA2 de la hemaglutinina de la influenza en el que se han mutado uno o más aminoácidos. También se proveen ácidos nucleicos que codifican dichos polipéptidos, composiciones que comprenden a los polipéptidos y/o a las moléculas de ácidos nucleicos; así como métodos para usarlos, en particular en la detección, la prevención y/o el tratamiento de la influenza.
MX2014006396A 2011-11-28 2012-11-27 Vacunas contra el virus de la influenza y sus usos. MX357009B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564198P 2011-11-28 2011-11-28
US201161564086P 2011-11-28 2011-11-28
EP11191009 2011-11-28
EP11191003 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
MX2014006396A true MX2014006396A (es) 2014-07-22
MX357009B MX357009B (es) 2018-06-22

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006396A MX357009B (es) 2011-11-28 2012-11-27 Vacunas contra el virus de la influenza y sus usos.

Country Status (20)

Country Link
US (3) US9452211B2 (es)
EP (2) EP3566714A1 (es)
JP (1) JP6294828B2 (es)
KR (1) KR101983989B1 (es)
CN (1) CN104066446B (es)
AR (1) AR089005A1 (es)
AU (1) AU2012343981B2 (es)
BR (1) BR112014012681A8 (es)
CA (1) CA2857087C (es)
EA (1) EA033386B1 (es)
HK (1) HK1199211A1 (es)
IL (1) IL232780A (es)
IN (1) IN2014CN04742A (es)
MX (1) MX357009B (es)
MY (1) MY170927A (es)
PH (1) PH12014501118B1 (es)
SG (1) SG11201402633UA (es)
TW (1) TWI618715B (es)
WO (1) WO2013079473A1 (es)
ZA (1) ZA201404797B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US9637522B2 (en) * 2012-05-23 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
WO2014099931A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3004142B1 (en) * 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP6704849B2 (ja) * 2013-08-03 2020-06-03 アバター・メディカル・エルエルシー インフルエンザヘマグルチニンタンパク質およびその方法
EP3137487B1 (en) * 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
EP3160998B1 (en) 2014-06-26 2019-08-21 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
PE20170291A1 (es) * 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
WO2016005480A1 (en) * 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CA2985402A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
CA2997181A1 (en) 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
IL303650B1 (en) * 2016-09-02 2024-10-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
CN110325208A (zh) * 2016-09-16 2019-10-11 威克斯技术公司 针对流感的疫苗接种的组合物和方法
EP3528827A4 (en) * 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. INFLUENZA HEMAGGLUTININ PROTEIN Vaccines
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
AU2018371355B2 (en) * 2017-11-22 2023-05-04 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
CA3089177A1 (en) 2018-01-23 2019-08-01 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
TW202016308A (zh) 2018-06-27 2020-05-01 加拿大商苜蓿股份有限公司 流感病毒血球凝集素突變體
JP2022530439A (ja) * 2019-04-25 2022-06-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー 組換えインフルエンザ抗原
KR20220057578A (ko) * 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
JP2022553258A (ja) * 2019-10-15 2022-12-22 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
WO2022051327A1 (en) * 2020-09-02 2022-03-10 St. Jude Children's Research Hospital, Inc. Hemagglutinin modifications for improved influenza vaccine production
CN116528893A (zh) 2020-09-07 2023-08-01 英特维特国际股份有限公司 用于ha抗体阳性靶标的ha茎疫苗
JP2024528504A (ja) * 2021-06-28 2024-07-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規インフルエンザ抗原
WO2024038382A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. Modified influenza viruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116874607A (zh) * 2023-06-09 2023-10-13 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2002012523A2 (en) 2000-08-10 2002-02-14 Crucell Holland B.V. Transduction of chondrocytes using adenoviral vectors
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DK1670925T3 (da) 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
KR101485197B1 (ko) 2006-09-07 2015-01-23 크루셀 홀란드 비.브이. 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
US9051359B2 (en) * 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
EP3248615A1 (en) * 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
KR101941724B1 (ko) 2011-07-14 2019-01-23 얀센 백신스 앤드 프리벤션 비.브이. 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
NZ628382A (en) 2012-03-08 2017-03-31 Janssen Vaccines & Prevention Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US9512201B2 (en) 2012-09-27 2016-12-06 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2016005480A1 (en) 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
PE20170291A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas

Also Published As

Publication number Publication date
US20140357845A1 (en) 2014-12-04
EA201491051A1 (ru) 2015-04-30
ZA201404797B (en) 2022-03-30
MY170927A (en) 2019-09-19
TW201329101A (zh) 2013-07-16
IN2014CN04742A (es) 2015-09-18
IL232780A (en) 2017-09-28
BR112014012681A2 (pt) 2017-06-13
KR101983989B1 (ko) 2019-05-31
JP2015502353A (ja) 2015-01-22
US9452211B2 (en) 2016-09-27
KR20140099515A (ko) 2014-08-12
AU2012343981B2 (en) 2017-09-07
CA2857087A1 (en) 2013-06-06
US20160355553A1 (en) 2016-12-08
PH12014501118A1 (en) 2014-08-04
NZ625973A (en) 2016-09-30
JP6294828B2 (ja) 2018-03-14
CA2857087C (en) 2021-05-25
WO2013079473A1 (en) 2013-06-06
EA033386B1 (ru) 2019-10-31
EP2785372B1 (en) 2019-06-19
US9969778B2 (en) 2018-05-15
TWI618715B (zh) 2018-03-21
HK1199211A1 (en) 2015-06-26
CN104066446B (zh) 2017-10-03
EP2785372A1 (en) 2014-10-08
PH12014501118B1 (en) 2014-08-04
CN104066446A (zh) 2014-09-24
IL232780A0 (en) 2014-07-31
MX357009B (es) 2018-06-22
EP3566714A1 (en) 2019-11-13
AU2012343981A1 (en) 2014-07-10
AR089005A1 (es) 2014-07-23
SG11201402633UA (en) 2014-09-26
US20160362455A1 (en) 2016-12-15
BR112014012681A8 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
PH12014501118A1 (en) Influenza virus vaccines and uses thereof
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
MX346206B (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
CY1119916T1 (el) Ανοσογονικη συνθεση
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
IN2014DN07399A (es)
IN2014DN05805A (es)
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
IN2014DN05695A (es)
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
EP3936141A3 (en) Anti-senescence compounds and uses thereof
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
SG10201908920QA (en) Influenza virus vaccines and uses thereof
WO2011138032A3 (en) Universal influenza vaccines and methods for their generation
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SANDVIK HYPERION AB

FG Grant or registration